Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × ficlatuzumab × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 Gastrointestinal 1 CNS 1

Conditions

Gliosarcoma 1 Glioblastoma 1

Interventions

Temozolomide 134 Radiotherapy 83 Cyclophosphamide 49 Radiation 39 Magnetic Resonance Spectroscopy 38 Bevacizumab 34 Irinotecan 30 Filgrastim 27 Radiosurgery 25 Specimen Handling 23 Topotecan 20 Nivolumab 20 Carboplatin 20 Etoposide 19 pembrolizumab 18 fludarabine 18 Melphalan 17 Surgical Procedures, Operative 16 Granulocyte Colony-Stimulating Factor 16 Vorinostat 15 Vincristine 15 sargramostim 14 Peripheral Blood Stem Cell Transplantation 12 Ipilimumab 12 Drug Therapy 12 Busulfan 12 Radiotherapy, Intensity-Modulated 11 O(6)-benzylguanine 11 Everolimus 11 Erlotinib Hydrochloride 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡